Related Experiment Video
Updated: Jun 3, 2026

Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy
Published on: September 20, 2024
Comprehensive care of children with Dravet syndrome
1Department of Pediatric Neuroscience, IRCCS Foundation Neurological Institute C Besta, Milano, Italy. granata@istituto-besta.it
Abstract:
The comprehensive care of a patient with Dravet syndrome encompasses both the "care" and the "cure" of the patient, and requires cooperation among family, doctors, and several other specialized caregivers to search for the attainment of the best quality of life for the patients and their families. Several issues peculiar to the disease to be faced while dealing with the patient are: (1) SMEI is an "evolving" disease that appears in an otherwise healthy child with symptoms that appear and mutate throughout the course of the disease; (2) the severity of the disease is not fully predictable at onset and appears to be individual-specific; (3) the seizures are invariably drug resistant and seizure freedom is not a realistic goal; and (4) in addition to seizures many other invalidating clinical problems, including cognitive impairment, behavior disorders, and a number of comorbidities characterize the disease course. The comprehensive caring must be physician-guided and patient-centered and implies a multidisciplinary approach to be built around the children and caregivers, who need to be guided through the steps of the diagnosis, treatments, and managements of the various comorbidities.
Related Concept Videos
Drug Dosing: Infants and Children
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Pharmaceutical Poisoning: Treatment Strategies
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Chronic Pancreatitis II: Collaborative Care
Assessment:
